246 related articles for article (PubMed ID: 21541661)
1. Lack of association between XPD Lys751Gln and Asp312Asn polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies.
Zhang Y; Ding D; Wang X; Zhu Z; Huang M; He X
Int J Colorectal Dis; 2011 Oct; 26(10):1257-64. PubMed ID: 21541661
[TBL] [Abstract][Full Text] [Related]
2. Xeroderma pigmentosum group D polymorphisms and esophageal cancer susceptibility: a meta-analysis based on case-control studies.
Yang R; Zhang C; Malik A; Shen ZD; Hu J; Wu YH
World J Gastroenterol; 2014 Nov; 20(44):16765-73. PubMed ID: 25469049
[TBL] [Abstract][Full Text] [Related]
3. XPD Lys751Gln and Asp312Asn polymorphisms and gastric cancer susceptibility: a meta-analysis of case-control studies.
Yin QH; Liu C; Hu JB; Meng RR; Li L; Wang YJ
Asian Pac J Cancer Prev; 2013; 14(1):231-6. PubMed ID: 23534729
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms of xeroderma pigmentosum group D gene Asp312Asn and Lys751Gln and susceptibility to prostate cancer: a systematic review and meta-analysis.
Ma Q; Qi C; Tie C; Guo Z
Gene; 2013 Nov; 530(2):309-14. PubMed ID: 23973729
[TBL] [Abstract][Full Text] [Related]
5. Association between XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma risk: a systematic review and meta-analysis.
Peng Q; Li S; Lao X; Chen Z; Li R; Qin X
Medicine (Baltimore); 2014 Dec; 93(29):e330. PubMed ID: 25546681
[TBL] [Abstract][Full Text] [Related]
6. Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis.
Li SX; Dai QS; Chen SX; Zhang SD; Liao XY; Deng X; Chi HB; Li FJ; Zhu JH; Jiang YY
Tumour Biol; 2014 Apr; 35(4):3905-15. PubMed ID: 24347488
[TBL] [Abstract][Full Text] [Related]
7. XPD Lys751Gln and Asp312Asn polymorphisms and susceptibility to skin cancer: a meta-analysis of 17 case-control studies.
Zhu HL; Bao JM; Lin PX; Li WX; Zou ZN; Huang YE; Chen Q; Shen H
Asian Pac J Cancer Prev; 2014; 15(16):6619-25. PubMed ID: 25169498
[TBL] [Abstract][Full Text] [Related]
8. Association between XPD Lys751Gln polymorphism and risk of head and neck cancer: a meta-analysis.
Yuan H; Niu YM; Wang RX; Li HZ; Chen N
Genet Mol Res; 2011 Nov; 10(4):3356-64. PubMed ID: 22179996
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in XPD (Asp312Asn and Lys751Gln) genes, sunburn and arsenic-related skin lesions.
McCarty KM; Smith TJ; Zhou W; Gonzalez E; Quamruzzaman Q; Rahman M; Mahiuddin G; Ryan L; Su L; Christiani DC
Carcinogenesis; 2007 Aug; 28(8):1697-702. PubMed ID: 17470448
[TBL] [Abstract][Full Text] [Related]
10. XPD Lys751Gln polymorphism and esophageal cancer susceptibility: a meta-analysis of case-control studies.
Ding DP; Ma WL; He XF; Zhang Y
Mol Biol Rep; 2012 Mar; 39(3):2533-40. PubMed ID: 21667112
[TBL] [Abstract][Full Text] [Related]
11. XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: a meta-analysis.
Yan Y; Liang H; Light M; Li T; Deng Y; Li M; Li S; Qin X
Tumour Biol; 2014 Mar; 35(3):1907-15. PubMed ID: 24101192
[TBL] [Abstract][Full Text] [Related]
12. XPD polymorphisms, cigarette smoking, and bladder cancer risk: a meta-analysis.
Wang M; Gu D; Zhang Z; Zhou J; Zhang Z
J Toxicol Environ Health A; 2009; 72(11-12):698-705. PubMed ID: 19492231
[TBL] [Abstract][Full Text] [Related]
13. XPD Lys(751)Gln and Asp (312)Asn polymorphisms and bladder cancer risk: a meta-analysis.
Li C; Jiang Z; Liu X
Mol Biol Rep; 2010 Jan; 37(1):301-9. PubMed ID: 19669592
[TBL] [Abstract][Full Text] [Related]
14. The association between XPD Asp312Asn polymorphism and lung cancer risk: a meta-analysis including 16,949 subjects.
Zhang J; Qiu LX; Leaw SJ; Hu XC; Chang JH
Med Oncol; 2011 Sep; 28(3):655-60. PubMed ID: 20354818
[TBL] [Abstract][Full Text] [Related]
15. XPD Lys751Gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28,709 subjects.
Qiu LX; Yao L; Zhang J; Zhu XD; Zhao XM; Xue K; Mao C; Chen B; Zhan P; Yuan H; Hu XC
Breast Cancer Res Treat; 2010 Nov; 124(1):229-35. PubMed ID: 20204500
[TBL] [Abstract][Full Text] [Related]
16. XPD Lys
Yang QI; Wei YF; Zhang Y; Huang GM
Exp Ther Med; 2015 Jun; 9(6):2406-2414. PubMed ID: 26136996
[TBL] [Abstract][Full Text] [Related]
17. XPA A23G, XPC Lys939Gln, XPD Lys751Gln and XPD Asp312Asn polymorphisms, interactions with smoking, alcohol and dietary factors, and risk of colorectal cancer.
Hansen RD; Sørensen M; Tjønneland A; Overvad K; Wallin H; Raaschou-Nielsen O; Vogel U
Mutat Res; 2007 Jun; 619(1-2):68-80. PubMed ID: 17363013
[TBL] [Abstract][Full Text] [Related]
18. XPD Lys751Gln polymorphisms and the risk of esophageal cancer: an updated meta-analysis.
Guo XF; Wang J; Lei XF; Zeng YP; Dong WG
Intern Med; 2015; 54(3):251-9. PubMed ID: 25748732
[TBL] [Abstract][Full Text] [Related]
19. XPD Asp312Asn polymorphism is a risk factor for prostate cancer.
Liao SG; Liu L; Wang Y; Zhang YY; Wang YJ
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1689-95. PubMed ID: 22644997
[TBL] [Abstract][Full Text] [Related]
20. The effect of XPD/ERCC2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis.
Xue H; Lu Y; Lin B; Chen J; Tang F; Huang G
PLoS One; 2012; 7(9):e43431. PubMed ID: 23028453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
